Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

Arthritis and Rheumatism

Volumn 64, Issue 3, 2012, Pages 617-629

  Fleischmann, Roy ^a   Cutolo, Maurizio ^b   Genovese, Mark C ^c   Lee, Eun Bong ^d   Kanik, Keith S ^e   Sadis, Seth ^e,f   Connell, Carol A ^e   Gruben, David ^e   Krishnaswami, Sriram ^e   Wallenstein, Gene ^e   Wilkinson, Bethanie E ^e   Zwillich, Samuel H ^e  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c STANFORD UNIVERSITY   (United States)

^d Seoul National University   (South Korea)

^e PFIZER INC   (United States)

^f Departments of Compendia Bioscience   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; TOFACITINIB;

ADULT; ARTICLE; BRONCHITIS; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG SUBSTITUTION; DRUG TOLERANCE; FEMALE; HEALTH STATUS; HUMANS; INJECTIONS, SUBCUTANEOUS; JANUS KINASE 3; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; PYRIMIDINES; PYRROLES; RECOVERY OF FUNCTION;

EID: 84857761516     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33383     Document Type: Article

References (14)

1. Ghoreschi K, Laurence A, O'Shea JJ,. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-87.
2. Vijayakrishnan L, Venkataramanan R, Gulati P,. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci 2011; 32: 25-34.
3. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010; 7: 41.
4. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dose levels of CP-690,550 versus placebo. Arthritis Rheum 2009; 60: 1895-905.
5. Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2010; 69: 413-6.
6. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone. Arthritis Rheum. In press.
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
8. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
9. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
10. Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
11. Ware JE Jr, Snow KK, Kosinski M, Gandek B,. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
12. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J,. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 811-9.
13. Woodworth TG, Furst DE, Strand V, Kempeni J, Fenner H, Lau CS, et al. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. J Rheumatol 2001; 28: 1163-9.
14. Van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508-16.